{"id":1381,"date":"2026-04-22T16:37:41","date_gmt":"2026-04-22T16:37:41","guid":{"rendered":"https:\/\/naturalhealthcontent.com\/index.php\/2026\/04\/22\/la-startup-neuro-tortugas-devoile-106-millions-de-dollars-et-un-pipeline-de-medicaments-pour-le-cerveau\/"},"modified":"2026-04-22T16:37:42","modified_gmt":"2026-04-22T16:37:42","slug":"la-startup-neuro-tortugas-devoile-106-millions-de-dollars-et-un-pipeline-de-medicaments-pour-le-cerveau","status":"publish","type":"post","link":"https:\/\/naturalhealthcontent.com\/index.php\/2026\/04\/22\/la-startup-neuro-tortugas-devoile-106-millions-de-dollars-et-un-pipeline-de-medicaments-pour-le-cerveau\/","title":{"rendered":"La startup Neuro Tortugas d\u00e9voile 106 millions de dollars et un pipeline de m\u00e9dicaments pour le cerveau"},"content":{"rendered":"

Tortugas Neuroscience launched quietly on Tuesday with $106 million<\/a> to support a portfolio of four licensed drugs currently in clinical development targeting various central nervous system indications.<\/p>\n

Based in Framingham, Massachusetts, Tortugas is focusing on neuroscientific targets validated by existing approved drugs. The startup aims to differentiate itself by offering advantages such as less frequent dosing; all its medications are designed to be taken as once-daily pills, a convenience compared to some neuromedicines that require multiple daily doses. In addition to improved drug properties, the company has stated that its molecules present expansion potential to other indications.<\/p>\n

The two most advanced drugs from Tortugas stem from the pharmaceutical group Hansoh. TRTL-107 is in Phase 2 development for schizophrenia and acts as a partial agonist of dopamine receptors D2 and D3, in addition to being an antagonist of 5-HT2A. While existing antipsychotics target these pathways, TRTL-107 aims to address them with a single molecule.<\/p>\n

The second drug from Hansoh, TRTL-913, is a positive allosteric modulator of the GABAA receptor. Medications in this class are typically used to treat conditions such as seizures, anxiety, and muscle spasms. Tortugas is developing TRTL-913 for tinnitus, a condition characterized by ringing or buzzing in the ears that is not caused by external sound. Currently, there are no FDA-approved medications for tinnitus, though clinicians sometimes prescribe off-label therapies for management.<\/p>\n

The two other drugs in Tortugas\u2019 clinical pipeline are sourced from Eisai. TRTL-729 is a non-competitive inhibitor of GAT-1, being developed for focal epilepsy, while TRTL-118 is a PDE9 inhibitor being explored for reversible encephalopathies. Additionally, Tortugas has reported a fifth program in the discovery phase targeting a confidential indication.<\/p>\n

“We believe each of our programs is well-positioned to differentiate in the market,” stated CEO Jeff Jonas in a prepared statement. “Tortugas has organized its portfolio of innovative therapeutic products that exhibit strong clinical differentiation potential and aim to reach specific patient markets.”<\/p>\n

Both Jonas and Tortugas\u2019 President and Head of R&D, Al Robichaud, are former leaders at the neuroscience developer Sage Therapeutics. In collaboration with Biogen, Sage’s Zurzuvae became the first FDA-approved oral medication for postpartum depression<\/a>, although this medication failed in studies for major depressive disorder<\/a>, an indication with greater revenue growth potential. Following Sage\u2019s exploration of strategic alternatives, the company was acquired by Supernus Pharmaceuticals<\/a> last year.<\/p>\n

The $106 million designated for Tortugas encompasses both a seed round and a Series A financing. Cure Ventures, where both Jonas and Robichaud are partners, led the seed round for the startup. Cure Ventures is also co-leading the Series A round alongside The Column Group and AN Venture Partners. Tortugas has indicated that this funding will support ongoing research and development, including the completion of Phase 2 trials for its schizophrenia and tinnitus drugs.<\/p>\n

Photo de Tortugas Neuroscience<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Tortugas Neuroscience launched quietly on Tuesday with $106 million to support a portfolio of four…<\/p>\n","protected":false},"author":1,"featured_media":1382,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[19],"tags":[],"class_list":["post-1381","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biopharma"],"_links":{"self":[{"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/posts\/1381","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/comments?post=1381"}],"version-history":[{"count":1,"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/posts\/1381\/revisions"}],"predecessor-version":[{"id":1383,"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/posts\/1381\/revisions\/1383"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/media\/1382"}],"wp:attachment":[{"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/media?parent=1381"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/categories?post=1381"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/naturalhealthcontent.com\/index.php\/wp-json\/wp\/v2\/tags?post=1381"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}